Carregant...
Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
Approximately half of metastatic cutaneous melanomas (CM) harbor a mutation in the BRAF protooncogene, upregulating the mitogen-activated protein kinase (MAPK)-pathway. The development of inhibitors targeting the MAPK pathway (MAPKi), i.e., BRAF- and MEK-inhibitors (BRAFi and MEKi), have substantial...
Guardat en:
| Publicat a: | Neoplasia |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Neoplasia Press
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8274243/ https://ncbi.nlm.nih.gov/pubmed/34246984 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2021.06.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|